Ownership Summary
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) currently has 7 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).
- Institutional ownership in Shuttle Pharmaceuticals Holdings edged up to 6.5% in September 2025, compared to 0.4% in June 2025.
- The company experienced a 4032.33% quarterly change in institutional shares held, alongside an increase of 40.00% in total owners annually.
- The latest 13F cycle for Shuttle Pharmaceuticals Holdings reveals that of 7 total investors, 5 funds grew their exposure, whereas 1 reduced theirs and 1 made no changes.
- The aggregate institutional position in Shuttle Pharmaceuticals Holdings now stands at 144.43K shares as of September 2025, after investors increased their holdings (up by 140.93K shares quarter on quarter which is up 114.63K shares year over year).
- The top institutional stake in Shuttle Pharmaceuticals Holdings as of September 30, 2025 belongs to Connective Capital Management, LLC, which owns 100.53K shares, or 4.50% of the company.
- Among the most significant buyers of Shuttle Pharmaceuticals Holdings during September 2025 were Connective Capital Management, LLC (100.53K), DRW Securities, LLC (42.83K), Tower Research Capital LLC (TRC) (892), MORGAN STANLEY (27), BANK OF AMERICA CORP /DE/ (5).
- Leading sellers of Shuttle Pharmaceuticals Holdings stock in September 2025 included UBS Group AG (3.36K).
- The top 7 institutional holders of Shuttle Pharmaceuticals Holdings for the quarter ending September 2025 included Connective Capital Management, LLC (100.53K), DRW Securities, LLC (42.83K), Tower Research Capital LLC (TRC) (1.01K), MORGAN STANLEY (27), BANK OF AMERICA CORP /DE/ (8), UBS Group AG (8), Federation des caisses Desjardins du Quebec (2).